Duchenne Muscular Dystrophy (DMD) is a life-threatening, sex-linked, pediatric rare disease, primarily affecting boys. It is characterized by progressive muscle degeneration, weakness, and eventually functional loss. DMD is caused by a mutation in the dystrophin gene, a protein needed to maintain muscle integrity, and for improving signaling and growth in differentiation of the muscle tissue. […]Read More
Author: Lora Hamuro
Dr. Lora Hamuro is a Senior Research Investigator at Bristol-Myers Squibb in Clinical Pharmacology & Pharmacometrics. She obtained a PhD in Biochemistry and Molecular Biology from the Pennsylvania State University, College of Medicine, MS in Pharmacometrics from the University of Maryland, and a Post-Doctoral Fellowship at the University of California, San Diego. She has over 10 years of pharmaceutical drug development experience, has published 30 peer-reviewed articles and book chapters, and is a member of ASCPT, ACCP, and AAPS. She is currently responsible for supporting Clinical Pharmacology of Immuno-oncology agents, and her interests include using disease progression modeling to inform clinical trial design.